Syringe filters that can handle water-based solutions with a long track record in HPLC and various organic solvents.
We would like to introduce our HPLC syringe filter, 'Ekicrodisc'. The water-based 'Ekicrodisc 3 and 13' reliably filters precious aqueous solution samples with minimal residual volume. Additionally, the 'Ekicrodisc 25' allows for observation of the filtration state due to its acrylic housing. The organic-based 'Ekicrodisc 3CR, 13CR, and 25CR' utilize a hydrophobic and chemically resistant PTFE membrane, making them suitable for filtering organic solvent samples. 【Features】 <Ekicrodisc 3 and 13 (Water-based)> ■ Versapor (acrylic copolymer) membrane provides high flow rates and reliable particle retention. ■ Minimal residual volume reduces sample loss. ■ Proven track record in HPLC for many years. *For more details, please refer to the PDF document or feel free to contact us.
Inquire About This Product
basic information
【Other Features】 <Ekicrodisc 25 (for aqueous solutions)> ■ Supor (polyether sulfone) membrane has ultra-low protein adsorption and ensures reliable particle retention. ■ Filtration status can be observed through the acrylic housing. ■ Proven track record in HPLC over many years. <Ekicrodisc 3CR・13CR・25CR (for organic solvents)> ■ Excellent chemical compatibility with a variety of solvents. ■ Minimal residual volume to reduce sample loss. ■ Can be sterilized by autoclaving. ■ Can also be used as a vent filter. ■ HPLC guaranteed. *For more details, please refer to the PDF document or feel free to contact us.
Price range
Delivery Time
Applications/Examples of results
【Usage】 ■ For sample pretreatment ■ For HPLC *For more details, please refer to the PDF document or feel free to contact us.
Company information
Cytiva and Pall Life Sciences have merged their businesses and will officially launch under the "Cytiva" brand on May 1, 2023. Under our mission of "Advancing therapies, faster," we will integrate both organizations and focus even more on supporting the development and manufacturing of better therapies for patients as a stronger global provider of technologies and services. The new Cytiva will offer a broader and deeper expertise and a rich lineup of products and services to better support various customers involved in research and the manufacturing and development of biopharmaceuticals, enabling them to deliver therapies to patients more quickly, from discovery to delivery. With a rich history spanning several hundred years, Pall Life Sciences and Cytiva, as part of the Danaher Group, will continue to unite to provide better services to our customers.